Jubivilda 50 M Forte Tablet SR is a combination oral antidiabetic medication containing Metformin 1000 mg and Vildagliptin 50 mg, designed for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves insulin sensitivity, thereby enhancing peripheral glucose uptake and utilization. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. This synergistic combination effectively improves glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. The sustained-release formulation of Jubivilda 50 M Forte ensures a gradual release of active ingredients, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with either agent is inadequate. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Jubivilda 50 M Forte should be used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.